- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
Patent holdings for IPC class C07D 207/14
Total number of patents in this class: 434
10-year publication summary
|
36
|
36
|
30
|
47
|
26
|
26
|
23
|
20
|
31
|
17
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2710 |
38 |
| Bristol-myers Squibb Company | 4751 |
16 |
| The Regents of the University of California | 20778 |
14 |
| Taisho Pharmaceutical Co., Ltd. | 850 |
12 |
| Mission Therapeutics Limited | 80 |
10 |
| Oryzon Genomics S.A. | 103 |
9 |
| Engrail Therapeutics, Inc. | 26 |
9 |
| F. Hoffmann-La Roche AG | 7819 |
8 |
| H. Lundbeck A/S | 1232 |
7 |
| Janssen Pharmaceutica N.V. | 3162 |
6 |
| Dana-Farber Cancer Institute, Inc. | 2665 |
6 |
| Tetraphase Pharmaceuticals, Inc. | 52 |
6 |
| Theravance Biopharma R&D IP, LLC | 362 |
6 |
| Chen, XI | 8 |
6 |
| Piazza, Gary A | 7 |
6 |
| Merck Sharp & Dohme LLC | 3736 |
6 |
| Boyd, Michael R. | 7 |
6 |
| Keeton, Adam B. | 7 |
6 |
| Mitsubishi Tanabe Pharma Corporation | 398 |
5 |
| Sanofi | 4307 |
5 |
| Other owners | 247 |